The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the monoclonal antibodies of a locomob and all the rakimab as well as in closer and can lower blood pressure about 20 to 25 percent and it seems that actually in those trials that individuals who had the higher leprogel a levels actually drive the greatest benefit from those therapies
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
you know we now have therapies that work in terms of lowering leverage a but what does that mean in terms of vent reduction
so they were never compared head to head so they have a lock of map and all of them have had a similar 15 reduction in major adverse cardiovascular events and in their respective trials the Fourier at Odyssey trials and they had similar reduction of hypertual a as well